Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study

Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study

<b>Background and aims</b>: The identification of patients with Hepatitis C Virus (HCV)-positive advanced chronic liver disease (aCLD) successfully treated by Direct Acting Antiviral Agents (DAAs) who really benefit from Hepatocellular Carcinoma (HCC) surveillance programs is still a mat...

Full description

Bibliographic Details
Main Authors: Alessia Ciancio, Davide Giuseppe Ribaldone, Matteo Spertino, Alessandra Risso, Debora Ferrarotti, Gian Paolo Caviglia, Patrizia Carucci, Silvia Gaia, Emanuela Rolle, Marco Sacco, Giorgio Maria Saracco
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Biomedicines
Subjects:
Hepatocellular Carcinoma
chronic hepatitis C
DAA
cirrhosis
FIB-4
Online Access:https://www.mdpi.com/2227-9059/11/1/166

Internet

https://www.mdpi.com/2227-9059/11/1/166

Similar Items